[go: up one dir, main page]

NO20083046L - Polymorfer av androgenreseptormodulator (N-3H-imidazo [4,5-B] pyridin-2-yl-metyl)-2-fluor-4-metyl-3-okso-4-aza-androst-1-en-17-beta-karboksamid - Google Patents

Polymorfer av androgenreseptormodulator (N-3H-imidazo [4,5-B] pyridin-2-yl-metyl)-2-fluor-4-metyl-3-okso-4-aza-androst-1-en-17-beta-karboksamid

Info

Publication number
NO20083046L
NO20083046L NO20083046A NO20083046A NO20083046L NO 20083046 L NO20083046 L NO 20083046L NO 20083046 A NO20083046 A NO 20083046A NO 20083046 A NO20083046 A NO 20083046A NO 20083046 L NO20083046 L NO 20083046L
Authority
NO
Norway
Prior art keywords
methyl
osteoporosis
disease
androgen
androgen receptor
Prior art date
Application number
NO20083046A
Other languages
English (en)
Inventor
Robert S Meissner
James J Perkins
Aaron S Cote
Lushi Tan
Wenjie Li
Joyce Stellabott
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37946325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083046(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20083046L publication Critical patent/NO20083046L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelser med strukturformel I er modulatorer for androgenreseptoren (AR) på en vevsselektiv måte. Disse forbindelsene er anvendbare ved økningen av svekket muskeltonus og behandlingen av tilstander forårsaket av androgen-mangel eller som kan lindres ved hjelp av androgenadministrering, inkludert osteoporose, osteopeni, glukokortikoid-indusert osteoporose, periodontalsykdom, benbrudd, benskade etter benrekonstruksjonskirurgi, sarkopeni, skrøpelighet, aldrende hud, mannlig hypogonadisme, postmenopausale symptomer hos kvinner, aterosklerose, hyperkolesterolemi, hyperlipi-demi, overvekt, aplastisk anemi og andre hemoatopoeseforstyrrelser, inflammatorisk artritt og leddreparasjon, HIV-utmagring, prostatakreft, benign prostatisk hyperplasi (BPH), abdominalfedme, metabolsk syndrom, type II-diabetes, kreftkakeksi, Alzheimers sykdom, muskulære dystrofier, kognitiv svikt, seksuell dysfunksjon, søvnapne, depresjon, for tidlig eggstokksvikt og autoimmunsykdom, alene eller i kombinasjon med andre aktive midler.
NO20083046A 2005-12-07 2008-07-04 Polymorfer av androgenreseptormodulator (N-3H-imidazo [4,5-B] pyridin-2-yl-metyl)-2-fluor-4-metyl-3-okso-4-aza-androst-1-en-17-beta-karboksamid NO20083046L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74802805P 2005-12-07 2005-12-07
PCT/US2006/046263 WO2007067490A1 (en) 2005-12-07 2006-12-04 POLYMORPHS OF ANDROGEN RECEPTOR MODULATOR - (N-3H-IMIDAZO [4 , 5-B] PYRIDIN-2-YL-METHYL) -2-FLUORO-4-METHYL-3-OXO-4-AZA-ANDROST- l-EN-17 . BETA . -CARBOXAMIDE

Publications (1)

Publication Number Publication Date
NO20083046L true NO20083046L (no) 2008-09-05

Family

ID=37946325

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083046A NO20083046L (no) 2005-12-07 2008-07-04 Polymorfer av androgenreseptormodulator (N-3H-imidazo [4,5-B] pyridin-2-yl-metyl)-2-fluor-4-metyl-3-okso-4-aza-androst-1-en-17-beta-karboksamid

Country Status (16)

Country Link
US (1) US7365202B2 (no)
EP (1) EP1960417B1 (no)
JP (1) JP2009518404A (no)
KR (1) KR20080074215A (no)
CN (1) CN101356185A (no)
AR (1) AR057217A1 (no)
AU (1) AU2006322046B2 (no)
CA (1) CA2631936A1 (no)
IL (1) IL191692A0 (no)
NO (1) NO20083046L (no)
NZ (1) NZ568550A (no)
PE (1) PE20071091A1 (no)
RU (1) RU2008127354A (no)
TW (1) TW200730505A (no)
WO (1) WO2007067490A1 (no)
ZA (1) ZA200804329B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20090048283A1 (en) * 2007-08-15 2009-02-19 Lee Claire H Salt of an androgen receptor modulator
EP2205552B1 (en) * 2007-09-11 2018-02-28 GTx, Inc. Crystalline polymorph of the selective androgen modulators (r) or (s)-n-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
CN101939009B (zh) * 2008-02-05 2013-07-17 哈博生物科学公司 药学固体形式
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
MX338831B (es) 2010-02-04 2016-05-03 Radius Health Inc Moduladores selectivos de receptores de androgenos.
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
PT3122426T (pt) 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
US10913736B2 (en) * 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
HRP20220619T1 (hr) 2016-06-22 2023-02-03 Ellipses Pharma Ltd Postupci za liječenje ar+ raka dojke
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات
GB202208151D0 (en) * 2022-06-01 2022-07-13 Nzp Uk Ltd Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187278A (en) 1990-08-27 1993-02-16 Merck & Co., Inc. Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-aza-5α-androstan-3-one steroids
CA2478186C (en) * 2002-03-13 2011-08-23 Merck & Co., Inc. Fluorinated 4-azasteroid derivatives as androgen receptor modulators
US7301026B2 (en) * 2005-05-05 2007-11-27 Merck & Co., Inc Process for making fluorinated 4-azasteroid derivatives

Also Published As

Publication number Publication date
CA2631936A1 (en) 2007-06-14
AU2006322046A1 (en) 2007-06-14
AU2006322046B2 (en) 2012-01-19
CN101356185A (zh) 2009-01-28
KR20080074215A (ko) 2008-08-12
RU2008127354A (ru) 2010-01-20
EP1960417B1 (en) 2012-10-17
US7365202B2 (en) 2008-04-29
PE20071091A1 (es) 2007-11-19
WO2007067490A1 (en) 2007-06-14
JP2009518404A (ja) 2009-05-07
US20070129548A1 (en) 2007-06-07
IL191692A0 (en) 2008-12-29
AR057217A1 (es) 2007-11-21
NZ568550A (en) 2011-09-30
ZA200804329B (en) 2009-04-29
TW200730505A (en) 2007-08-16
EP1960417A1 (en) 2008-08-27

Similar Documents

Publication Publication Date Title
NO20083046L (no) Polymorfer av androgenreseptormodulator (N-3H-imidazo [4,5-B] pyridin-2-yl-metyl)-2-fluor-4-metyl-3-okso-4-aza-androst-1-en-17-beta-karboksamid
NO20070085L (no) N-(2-benzyl)-2-fenylbutanamider som androgenreseptormodulatorer
NO20090591L (no) Metabolisme modulatorer samt behandling av lidelser relatert dertil
WO2003092588A3 (en) 4-azasteroid derivatives as androgen receptor modulators
MX2008003634A (es) Moduladores del metabolismo y tratamiento de los trastornos metabolicos.
WO2005005606A3 (en) 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
WO2007041365A3 (en) 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
WO2007145835A3 (en) Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity
FR2908981B1 (fr) Tete de massage et/ou de distribution d'un produit et dispositif pourvu d'une telle tete
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
UA103901C2 (ru) Замещенные производные сульфамидов
BRPI0506970A (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
MXPA06012143A (es) Arilsulfonamidas y usos relacionados con las mismas.
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
TW200637535A (en) Aryl sulfones and uses related thereto
NO20064982L (no) 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav
WO2005117979A3 (en) Use of il-17 in the treatment of fertility-related disorders
WO2006026196A3 (en) Androgen receptor modulators
WO2008048540A3 (en) 2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators
WO2005005380A3 (en) 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
WO2006065600A3 (en) N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto
WO2005004807A3 (en) 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
WO2005044988A3 (en) 21-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
WO2010011597A3 (en) Treatment of obesity and related disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application